Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1)

Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two Phase 1 studies in patients with advanced or metastatic solid tumors, including patients with active CNS disease. Here we summarize the overall safety and report the antitumor activity of entre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Discov
Main Authors: Drilon, Alexander, Siena, Salvatore, Ou, Sai-Hong Ignatius, Patel, Manish, Ahn, Myung Ju, Lee, Jeeyun, Bauer, Todd M., Farago, Anna F., Wheler, Jennifer J., Liu, Stephen V., Doebele, Robert, Giannetta, Laura, Cerea, Giulio, Marrapese, Giovanna, Schirru, Michele, Amatu, Alessio, Bencardino, Katia, Palmeri, Laura, Sartore-Bianchi, Andrea, Vanzulli, Angelo, Cresta, Sara, Damian, Silvia, Duca, Matteo, Ardini, Elena, Li, Gang, Christiansen, Jason, Kowalski, Karey, Johnson, Ann, Patel, Rupal, Luo, David, Chow-Maneval, Edna, Hornby, Zachary, Multani, Pratik S., Shaw, Alice T., De Braud, Filippo G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5380583/
https://ncbi.nlm.nih.gov/pubmed/28183697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-1237
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados